Snowden Capital Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.57M | Buy |
127,299
+25,212
| +25% | +$671K | 0.1% | 218 |
|
|
2025
Q4 | $2.54M | Buy |
102,087
+2,176
| +2% | +$54.9K | 0.07% | 284 |
|
|
2025
Q3 | $2.55M | Sell |
99,911
-4,808
| -5% | -$119K | 0.07% | 272 |
|
|
2025
Q2 | $2.54M | Sell |
104,719
-37,574
| -26% | -$876K | 0.08% | 259 |
|
|
2025
Q1 | $3.61M | Buy |
142,293
+7,575
| +6% | +$198K | 0.12% | 195 |
|
|
2024
Q4 | $3.57M | Sell |
134,718
-97,289
| -42% | -$2.64M | 0.11% | 192 |
|
|
2024
Q3 | $6.71M | Sell |
232,007
-65,544
| -22% | -$1.91M | 0.2% | 108 |
|
|
2024
Q2 | $8.33M | Sell |
297,551
-2,202
| -0.7% | -$60.6K | 0.25% | 91 |
|
|
2024
Q1 | $8.32M | Buy |
299,753
+59,327
| +25% | +$1.65M | 0.26% | 88 |
|
|
2023
Q4 | $6.92M | Sell |
240,426
-7,865
| -3% | -$238K | 0.26% | 93 |
|
|
2023
Q3 | $8.24M | Sell |
248,291
-92,021
| -27% | -$3.25M | 0.35% | 57 |
|
|
2023
Q2 | $12.5M | Sell |
340,312
-51,518
| -13% | -$2.01M | 0.45% | 36 |
|
|
2023
Q1 | $16M | Buy |
391,830
+16,052
| +4% | +$693K | 0.62% | 22 |
|
|
2022
Q4 | $19.3M | Sell |
375,778
-33,838
| -8% | -$1.62M | 0.81% | 14 |
|
|
2022
Q3 | $17.9M | Buy |
409,616
+14,238
| +4% | +$692K | 0.81% | 11 |
|
|
2022
Q2 | $20.7M | Sell |
395,378
-2,933
| -0.7% | -$149K | 0.93% | 9 |
|
|
2022
Q1 | $20.6M | Buy |
398,311
+149,328
| +60% | +$7.75M | 0.82% | 10 |
|
|
2021
Q4 | $14.7M | Sell |
248,983
-14,905
| -6% | -$738K | 0.75% | 13 |
|
|
2021
Q3 | $11.3M | Buy |
263,888
+6,785
| +3% | +$301K | 0.57% | 21 |
|
|
2021
Q2 | $10.1M | Buy |
257,103
+10,194
| +4% | +$396K | 0.5% | 31 |
|
|
2021
Q1 | $8.95M | Buy |
246,909
+5,635
| +2% | +$200K | 0.51% | 28 |
|
|
2020
Q4 | $8.88M | Sell |
241,274
-999
| -0.4% | -$36.6K | 0.59% | 28 |
|
|
2020
Q3 | $8.44M | Buy |
242,273
+18,519
| +8% | +$649K | 0.68% | 19 |
|
|
2020
Q2 | $6.94M | Sell |
223,754
-3,099
| -1% | -$105K | 0.59% | 29 |
|
|
2020
Q1 | $7.03M | Buy |
226,853
+17,844
| +9% | +$608K | 0.77% | 21 |
|
|
2019
Q4 | $7.77M | Buy |
209,009
+19,381
| +10% | +$690K | 0.69% | 23 |
|
|
2019
Q3 | $6.46M | Buy |
189,628
+13,187
| +7% | +$480K | 0.65% | 27 |
|
|
2019
Q2 | $7.25M | Buy |
176,441
+2,425
| +1% | +$96.3K | 0.74% | 21 |
|
|
2019
Q1 | $7.01M | Buy |
174,016
+4,953
| +3% | +$198K | 0.77% | 19 |
|
|
2018
Q4 | $7M | Buy |
169,063
+10,179
| +6% | +$423K | 0.91% | 11 |
|
|
2018
Q3 | $6.64M | Buy |
158,884
+7,870
| +5% | +$303K | 0.75% | 19 |
|
|
2018
Q2 | $5.2M | Sell |
151,014
-5,133
| -3% | -$175K | 0.67% | 25 |
|
|
2018
Q1 | $5.26M | Buy |
156,147
+10,020
| +7% | +$344K | 0.77% | 23 |
|
|
2017
Q4 | $5.02M | Buy |
146,127
+10,122
| +7% | +$345K | 0.72% | 25 |
|
|
2017
Q3 | $4.61M | Buy |
136,005
+4,454
| +3% | +$143K | 0.74% | 24 |
|
|
2017
Q2 | $4.19M | Buy |
131,551
+7,067
| +6% | +$223K | 0.79% | 23 |
|
|
2017
Q1 | $4.04M | Buy |
124,484
+21,925
| +21% | +$691K | 0.89% | 17 |
|
|
2016
Q4 | $3.16M | Buy |
102,559
+917
| +0.9% | +$28K | 0.8% | 25 |
|
|
2016
Q3 | $3.27M | Buy |
101,642
+12,213
| +14% | +$408K | 0.88% | 23 |
|
|
2016
Q2 | $2.99M | Buy |
89,429
+7,526
| +9% | +$240K | 0.91% | 23 |
|
|
2016
Q1 | $2.3M | Buy |
+81,903
| New | +$2.34M | 0.79% | 29 |
|
Other funds holding PFE
VCM
VPM
Snowden Capital Advisors's PFE Position: Q1 2026 in Review
Snowden Capital Advisors increased its Pfizer (PFE) stake by 25% in Q1 2026, buying an estimated $671K and bringing the position to 127,299 shares worth $3.57M. The position accounts for 0.1% of the portfolio, ranked #218.
Snowden Capital Advisors first reported a position in PFE in Q1 2016 and has held it in 41 quarters since. The position peaked at $20.7M in Q2 2022. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Snowden Capital Advisors held 127,299 shares of Pfizer worth $3.57M as of Q1 2026.
- Snowden Capital Advisors bought 25,212 Pfizer shares in Q1 2026, an estimated $671K.
- Pfizer made up 0.1% of Snowden Capital Advisors's portfolio in Q1 2026, its #218 holding.
- Snowden Capital Advisors first reported a position in Pfizer in Q1 2016 and has held it in 41 quarters since.
- Snowden Capital Advisors's Pfizer position peaked at $20.7M in Q2 2022.
- 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.